Scilex Holding Company Net Assets
Scilex Holding Company net assets. Based on the latest financial reports, Scilex Holding Company (SCLX) has net assets worth $-310.49 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($253.56 Million) and total liabilities ($564.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Scilex Holding Company equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-310.49 Million |
| % of Total Assets | -122.45% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of Scilex Holding Company (2020–2025)
Net assets of Scilex Holding Company from 2020 to 2025. This chart illustrates how Scilex Holding Company's net assets have evolved over time, based on quarterly financial data. See Scilex Holding Company balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Scilex Holding Company (2020–2025)
The table below shows the annual net assets of Scilex Holding Company from 2020 to 2025. For live market cap and overall valuation, see Scilex Holding Company (SCLX) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-211.75 Million | -9.92% |
| 2024-12-31 | $-192.64 Million | -11.39% |
| 2023-12-31 | $-172.94 Million | -577.22% |
| 2022-12-31 | $36.24 Million | +116.19% |
| 2021-12-31 | $-223.88 Million | -58.01% |
| 2020-12-31 | $-141.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Scilex Holding Company's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 65766000100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Scilex Holding Company Net Assets Breakdown (December 2025)
Scilex Holding Company net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Comprehensive Income | $-5.80 Million | % |
| Other Components | $719.81 Million | % |
| Total Equity | $-207.78 Million | 100.00% |
Scilex Holding Company Competitors by Market Cap
The table below lists competitors of Scilex Holding Company ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Reborn Coffee Inc
NASDAQ:REBN
|
$13.02 Million |
|
Moleculin Biotech Inc
NASDAQ:MBRX
|
$13.02 Million |
|
Dyadic International Inc
NASDAQ:DYAI
|
$13.03 Million |
|
Stallion Uranium Corp.
V:STUD
|
$13.03 Million |
|
Nafpaktos Textile Industry S.A
AT:NAYP
|
$13.01 Million |
|
Imexhs Ltd
AU:IME
|
$13.00 Million |
|
INOVIQ LTD.
F:EGQ0
|
$13.00 Million |
|
Mico BioMed Co. Ltd.
KQ:214610
|
$13.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scilex Holding Company's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -192,641,000 to -207,781,000, a change of -15,140,000.
- Net loss of 358,734,000 reduced equity.
- Other comprehensive income decreased equity by 12,120,000.
- Other factors increased equity by 355,714,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-358.73 Million | -172.65% |
| Other Comprehensive Income | $-12.12 Million | -5.83% |
| Other Changes | $355.71 Million | +171.2% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Scilex Holding Company's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-35.15 | $1.85 | x |
| 2021-12-31 | $-58.98 | $1.85 | x |
| 2022-12-31 | $9.45 | $1.85 | x |
| 2023-12-31 | $-46.46 | $1.85 | x |
| 2024-12-31 | $-27.71 | $1.85 | x |
| 2025-12-31 | $-18.83 | $1.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scilex Holding Company utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1185.78%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-10.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -201.69% | 0.29x | 0.00x | $-33.35 Million |
| 2021 | 0.00% | -282.35% | 0.40x | 0.00x | $-66.04 Million |
| 2022 | -64.47% | -61.43% | 0.44x | 2.39x | $-26.99 Million |
| 2023 | 0.00% | -244.59% | 0.46x | 0.00x | $-97.04 Million |
| 2024 | 0.00% | -128.66% | 0.61x | 0.00x | $-53.54 Million |
| 2025 | 0.00% | -1185.78% | 0.08x | 0.00x | $-337.96 Million |
Industry Comparison
This section compares Scilex Holding Company's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $16,554,522,824
- Average return on equity (ROE) among peers: 23.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scilex Holding Company (SCLX) | $-310.49 Million | 0.00% | N/A | $13.01 Million |
| AbbVie Inc (ABBV) | $5.10 Billion | 104.16% | 12.89x | $356.49 Billion |
| Amgen Inc (AMGN) | $163.50 Million | 1.04% | 0.18x | $198.99 Billion |
| Amarin Corporation PLC (AMRN) | $-129.19 Million | 0.00% | 0.00x | $252.68 Million |
| AstraZeneca PLC (AZN) | $40.87 Billion | 17.21% | 1.55x | $282.04 Billion |
| AstraZeneca PLC (AZN) | $10.34 Billion | 11.05% | 0.92x | $246.25 Billion |
| Biogen Inc (BIIB) | $239.00 Million | 3.01% | 0.06x | $32.27 Billion |
| Bristol-Myers Squibb Company (BMY) | $10.56 Billion | 20.50% | 1.48x | $126.06 Billion |
| Gilead Sciences Inc (GILD) | $20.50 Billion | 22.57% | 2.43x | $182.40 Billion |
| GlaxoSmithKline PLC ADR (GSK) | $1.10 Billion | 36.36% | 0.64x | $111.15 Billion |
| Johnson & Johnson (JNJ) | $76.80 Billion | 23.36% | 1.44x | $574.95 Billion |
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve… Read more